Pillar / Money
Tirzepatide Cost Without Insurance
Without insurance, brand Zepbound costs $299 to $449 a month on Lilly’s self-pay card (last read October 15, 2026; Lilly refused our November 20 re-read), and the FDA-approved pills Foundayo and Wegovy start at $149. Compounded tirzepatide runs $69 to $299 a month across the 33 programs in our November 20, 2026 index (median $149); NexLife charges $129 month to month, or $115 a month on a 12-month plan.
Start with the manufacturer, not a platform
The single most expensive mistake in self-pay GLP-1 purchasing is buying a brand-name drug through a telehealth platform that resells it near retail. Our dataset contains brand Wegovy at $1,794 a month all-in from one provider and brand Mounjaro at $2,048 from another. NovoCare sells Wegovy direct for $349. Lilly runs no self-pay programme for Mounjaro, but Zepbound is the same molecule at $299 to $449.
That is a four to twelvefold difference for the identical medicine, and it is disclosed pricing rather than fraud. Price any brand drug at LillyDirect or NovoCare before buying it anywhere else.
The self-pay ladder in 2026
$110–$147 — compounded microdose programmes, on twelve-month plans. Below every dose studied in the trials.
$149 — FDA-approved oral orforglipron or oral Wegovy tablets, at starting doses. Reviewed for safety, effectiveness and quality.
$169–$215 — the lower band of standard compounded injectable programmes.
$299–$449 — brand Zepbound direct from LillyDirect, by dose tier.
$278–$399 — the upper band of compounded programmes, which overlaps the brand band.
Where self-pay logic breaks down
The overlap in that ladder is the finding. A compounded programme at $349 costs more than the approved injectable at $299 and more than twice the approved oral. Whatever the argument for compounded medicine is at that price, it is not a cost argument.
The cost argument holds firmly at the bottom of the range, and it holds for flat-rate programmes at maintenance doses, where a dose-independent price beats a brand tier that rises to $449.
Before you conclude you have no coverage
Three checks are worth the twenty minutes, because any of them beats every self-pay figure above.
- Check your plan's formulary directly for Zepbound and Wegovy, and check whether the exclusion is for weight management specifically. Coverage for a diabetes indication is often separate.
- Ask about prior authorisation criteria. Many plans cover with documentation of BMI and comorbidities.
- Check manufacturer savings programmes, which are separate from the self-pay pricing above and have their own eligibility rules.
Where a commercial plan covers either brand, the cost can fall to roughly $25 a month. No self-pay route competes with that, and no compounded programme comes close.
Show this figure as a table
| Item | Mean reduction | Evidence |
|---|---|---|
| Tirzepatide 15 mg (SURMOUNT-1) | 21% | Verified |
| Oral semaglutide 25 mg, adherent (OASIS 4) | 17% | Verified |
| Injectable semaglutide 2.4 mg (SURMOUNT-5) | 14% | Verified |
| Oral semaglutide 25 mg, treatment-policy (OASIS 4) | 14% | Verified |
| Orforglipron 17.2 mg (ATTAIN-1) | 12% | Reported |
| Liraglutide (SCALE) | 8% | Reported |
| Product | Starting self-pay price | Reported mean reduction | Trial |
|---|---|---|---|
| Zepbound (tirzepatide) injectable | $299/mo direct | about 20.9% at 15 mg | SURMOUNT-1, 72 weeks |
| Wegovy pill (oral semaglutide 25 mg) | $149/mo starting dose | 13.6–16.6% depending on estimand | OASIS 4, 64 weeks |
| Wegovy injectable (semaglutide 2.4 mg) | $349/mo maintenance | about 13.7% | SURMOUNT-5, 72 weeks |
| Foundayo (orforglipron) | $149/mo starting dose | about 11–12.4% at 17.2 mg | ATTAIN-1, 72 weeks |
NexLife is our #1 pick, not the lowest price we track. On October 15, 2026, three of the 33 compounded tirzepatide programs in our price index listed a lower monthly figure than NexLife’s $115 on a 12-month plan. NexLife charges $129 a month month to month (read November 6, 2026).
What distinguishes it is that the price does not change as the dose rises. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so most patients titrate upward within weeks. Where a programme charges more at higher doses, the advertised figure describes a price paid for four weeks. NexLife (opens nexlife.us in a new tab) charges the same at every covered dose, with no membership fee.
Its prices are dated. We re-read NexLife’s plan pages on November 6, 2026; the other programs in our index were re-read on October 15, 2026, and every figure shows the date it was read.
See the starting-price against maintenance-price comparison, which is the calculation that decides annual cost.
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | — | — | — |
| Found — compounded injectable | $169 | — | — | — |
| Enhance.MD — compounded microdose | $169 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Pending | $1,548 Pending | Flat at every dose Reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Pending | Flat at every dose Verified |
| Shed — compounded microdose | $199 | — | — | — |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | — | — | — |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Pending | Flat at every dose Verified |
| Shed — compounded injectable | $245 | — | — | — |
| Mochi Health — compounded injectable | $278 | — | — | — |
| Enhance.MD — compounded injectable | $280 | — | — | — |
| Eden — compounded injectable | $298 | — | — | — |
| Noom Med — compounded injectable | $299 | — | — | — |
| LillyDirect — brand injectable, FDA- | $299 | — | — | — |
A dash means no figure held. How we grade evidence.
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Reported |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Reported |
Show this figure as a table
| Item | Orforglipron | Oral Wegovy |
|---|---|---|
| FDA-approved oral, starter | $149 | $149 |
| FDA-approved injectable, direct | $299 | $449 |
| Compounded, lower band | $169 | $133 |
| Compounded, upper band | $399 | $299 |
| Brand resold near retail | $1,794 | $2,048 |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Pricing dataset, CSV · Pricing dataset, JSON
Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.
Questions readers actually ask
How much does Zepbound cost without insurance?
Without insurance, Lilly's Zepbound self-pay savings card listed the KwikPen at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg when each refill is bought within 45 days, according to Lilly's coverage page read October 15, 2026. Miss that window and the regular prices apply: $499 at 7.5 mg and $699 at 10 to 15 mg. The card covers up to 11 fills a calendar year, and its savings end December 31, 2026. Compounded tirzepatide costs less in our index, but it is not FDA-approved and is not the same product as Zepbound.
What is the cheapest way to get tirzepatide without insurance?
For the approved drug, LillyDirect at $299 for the starter vial. For the cheapest approved GLP-1 of any kind, orforglipron or oral Wegovy tablets at $149. Compounded programmes start lower but are not FDA-approved.
Should I buy brand drugs through a telehealth platform?
Price it at the manufacturer first. Some platforms resell brand drugs at four to twelve times the manufacturer's own direct self-pay price.
Related on this site
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Most Affordable Tirzepatide Online: Verified All-In CostsPillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Tirzepatide Cost in 2026Pillar / Money
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Best Month-to-Month Tirzepatide ProgramsPillar / Money
- BMI CalculatorTools
- Authors and AnalystsCore & Trust
Related coverage
Tirzepatide Ranked. “Tirzepatide Cost Without Insurance.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/tirzepatide-cost-without-insurance/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.